Last reviewed · How we verify
NCT05365607
NightWare and Cardiovascular Health in Adults With PTSD
NA trial testing NightWare in Posttraumatic Stress Disorder in 40 participants. Completed in 18 August 2024.
15 August 2024
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 24 June 2022 |
| Primary completion | 15 August 2024 |
| Estimated completion | 18 August 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- NightWare
- Sham NightWare
Conditions studied
- Posttraumatic Stress Disorder — all drugs for Posttraumatic Stress Disorder →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Autonomic Dysfunction — all drugs for Autonomic Dysfunction →
- Vascular Stiffness — all drugs for Vascular Stiffness →
Sponsor
University of Colorado, Denver
Who can join
Adults 22 to 99, any sex, with Posttraumatic Stress Disorder or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular aging and autonomic function in adults with nightmares related to PTSD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05365607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NightWare
Trials testing the same drug.
- NCT06419959 — NightWare and Cardiovascular Health in Veterans With PTSD · NA · recruiting
Other recruiting trials for Posttraumatic Stress Disorder
Currently open trials in the same condition.
- NCT04529031 — Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry · NA · recruiting
- NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
- NCT07176273 — Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD) · NA · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT06608277 — Ketamine, SGB and Combination Treatment for TBI · Phase 2 · recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05365607 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 8 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05365607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing